Genzyme's Manufacturing Problems
Executive Summary
Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.You may also be interested in...
Sanofi Pursues Genzyme, But For How Long?
Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: